Join us for our May Virtual research Forum with guest researcher Matt Cooper, Professor of Chemical Biology at the Institute of Molecular Bioscience, University of Queensland. In 2016 Professor Cooper co-founded Inflazome, a pioneering biotech company developing orally drugs to stop harmful neuroinflammatory that drives many diseases, including Parkinson’s.
Inflazome, which was sold to Roche in 2020, led the development of a novel class of drugs to address clinical unmet needs in inflammatory diseases by targeting danger sensors in the immune cells of our brain called inflammasomes. These are thought to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease and arthritis. This will be a very interesting presentation not to be missed.
If you missed the presentation you can view the slides below.